停用阿里皮普拉对缓解性重度抑郁症的影响:一项随机的安慰剂控制试验
Masahiro Takeshima1, Akise Umakoshi2, Yuki Omori3
1Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan. m.takeshima@med.akita-u.ac.jp.
Psychopharmacology
|March 28, 2024
概括
在缓解期的大型抑郁症 (MDD) 患者中,停止阿里皮普拉增强疗法 (AATA) 在这个小研究中没有增加复发风险. 需要进一步的研究来证实这些发现对MDD治疗.
科学领域:
- 精神病学是一个精神病学.
- 临床神经科学 临床神经科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 使用阿里皮普拉 (AATA) 进行抗抑郁药物增强疗法,对严重抑郁症 (MDD) 有效.
- 在MDD患者实现缓解后停止服用阿里皮普拉的影响尚不清楚.
- 现有的研究缺乏关于AATA持续后缓解的长期影响的数据.
研究的目的:
- 为了调查在患者中AATA停止后MDD复发的风险,在患者中实现了缓解.
- 在受控试验环境中评估AATA停药的安全性和有效性.
- 为未来关于MDD中AATA退出的研究提供初步数据.
主要方法:
- 进行了一项为期24周的多中心,安慰剂控制,双盲,随机化试验.
- 在AATA后缓解MDD的参与者被随机分配到继续或停止服用阿里皮普拉.
- 使用DSM-5标准评估复发情况,使用经过验证的尺度测量症状严重程度/社会功能. 使用了生存分析和混合效应模型.
主要成果:
- 23名参与者被随机分配. 在停用阿里皮普拉和安慰剂组之间没有观察到MDD复发率的显著差异 (p=0.642).
- 两组之间没有发现抑郁症状严重程度或社会功能方面的显著差异.
- 没有患者经历过额外皮拉米德症状或阿卡西西亚,这表明耐受性良好.
结论:
- 由于样本规模较小,无法得出关于AATA停止和MDD复发的最终结论.
- 这项研究作为一个基本的调查,在缓解MDD患者中停止阿里皮普拉的安全性.
- 建议进行更大规模,充足的研究,以证实这些初步发现,并为临床实践提供信息.
更多相关视频
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
47
04:33Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
676
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
228
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
228
01:28Psychosis and Antipsychotic Drugs: Overview
248
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
248
01:26Psychosis: Goals of Pharmacotherapy
125
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
125
01:24Mania and Antimanic Drugs: Overview
176
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
176
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
382
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
382
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
134
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
134